newsfilter
← Latest News
GlobeNewswire·

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906)

Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk's Rare Disease portfolioOmeros is eligible to receive 340 million US dollars in upfront and near-term